Table 4. PTA for the different fosfomycin dosing regimens in critically ill patients at steady state with a target of %fTime/MIC = 100 and the CFR of fosfomycin monotherapy and combinations with various dosing regimens.

Daily dose	Regimens	Infusion time (h)	PTA (%)									CFR (%)
			FOF MIC (µg/mL) against CRAB isolates									FOF (mono)	FOF (with CST)
			4	8	16	32	64	128	256	512	1,024
12 g	4 g q8h	0.5	100	100	100	98	93	80	47	5	0	35	74
		2	100	100	100	98	94	81	49	5	0	36	75
		4	100	100	100	99	95	84	51	5	0	37	78
	3 g q6h	2	100	100	100	99	95	83	53	8	0	39	77
		4	100	100	100	99	96	85	55	8	0	40	79
	12 g	24	100	100	100	100	98	89	59	10	0	43	82
16 g	4 g q6h	2	100	100	100	99	97	90	68	25	0	50	84
		4	100	100	100	100	98	92	70	26	0	52	86
	16 g	24	100	100	100	100	99	94	74	29	0	54	88
18 g	6 g q8h	0.5	100	100	100	99	97	90	69	26	0	51	84
		2	100	100	100	99	98	91	71	28	0	52	85
		4	100	100	100	100	98	92	72	28	0	53	86
	18 g	24	100	100	100	100	100	96	79	37	1	59	90
20 g	5 g q6h	2	100	100	100	100	99	93	77	41	2	58	88
		4	100	100	100	100	99	95	80	42	2	60	89
	20 g	24	100	100	100	100	100	97	83	46	3	62	91
24 g	8 g q8h	0.5	100	100	100	99	98	94	80	46	4	61	89
		2	100	100	100	100	98	94	81	48	4	61	89
		4	100	100	100	100	99	95	83	51	5	63	90
	6 g q6h	2	100	100	100	100	99	96	83	53	7	64	91
		4	100	100	100	100	99	97	85	54	8	65	92
	24 g	24	100	100	100	100	100	98	89	59	10	68	93

Color codes Strongly recommended dose based on ≥90% PTA or ≥90% CFR.

Moderately recommended dose based on 80% - 89% PTA or 80% - 89% CFR.

PTA, probability of target attainment; MIC, minimum inhibitory concentration; CFR, cumulative fraction of response; FOF, fosfomycin; CRAB, carbapenem-resistant Acinetobacter baumannii; CST, colistin.